Email this article Choroid plexus papilloma and atypical choroid plexus papilloma in children: treatment results
- Authors: Valiakhmetova A.F.1,2, Papusha L.I.1, Sanakoeva A.V.1, Shishkina L.V.2, Budanov O.I.1, Novichkova G.A.1, Gorelyshev S.K.2, Karachunskiy A.I.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- N.N. Burdenko National Medical Research Center of Neurosurgery
- Issue: Vol 20, No 4 (2021)
- Pages: 33-41
- Section: ORIGINAL ARTICLES
- Submitted: 21.12.2021
- Accepted: 21.12.2021
- Published: 21.12.2021
- URL: https://hemoncim.com/jour/article/view/564
- DOI: https://doi.org/10.24287/1726-1708-2021-20-4-33-41
- ID: 564
Cite item
Full Text
Abstract
Choroid plexus tumors (CPTs) are rare intraventricular tumors, accounting 2–5% of brain tumors in children. Choroid plexus papilloma (CPP) classified by the World Health Organization (WHO) on the basis of histological criteria as benign tumor (WHO grade I), CPPs accounts for 10–20% of brain tumors during the first year of life, the median age of patients with CPP at the time of diagnosis – 3.5 years. Atypical choroid plexus papilloma (APP) is an intermediate (WHO grade II) tumor which was officially included in the WHO classification in 2007. Median age 0,63 years. In this work, for the first time in the Russian literature, we present the outcomes of CPP and APP therapy in a large cohort of patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. In our study from January 1, 2009 to December 31, 2019, 83 CPP and 37 APP were histologically verified. For all patients, surgical removal of the tumor was the first stage of treatment. In 79 (95.2%) patients with CPP and in 32 (86.5%) children with APP, radical resection was performed at the first stage. In 73.5% of children with CPP and 62.2% of children with APP there was no intra- and postoperative complications. In both CPP and APP, the 5-year EFS in patients with complete resection was statistically significantly higher compared to subtotal tumor resection (100% and 33 ± 27% in CPP, 94 ± 4% and 25 ± 22% for APP) (p < 0.001). Chemoradiation therapy was given to 1 patient with CPP, 4 patients with APP with tumor recurrence/progression.
About the authors
A. F. Valiakhmetova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation;N.N. Burdenko National Medical Research Center of Neurosurgery
Author for correspondence.
Email: andgeval@gmail.com
ORCID iD: 0000-0002-2977-665X
a junior researcher at the Department of Treatment Optimization for CNS Tumours, 1 Samory Mashela St., Moscow 117997;
a pediatric oncologist at the 1st Department of Neurosurgery, Moscow
Russian FederationL. I. Papusha
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-7750-5216
1 Samory Mashela St., Moscow 117997
Russian FederationA. V. Sanakoeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-5893-0508
1 Samory Mashela St., Moscow 117997
Russian FederationL. V. Shishkina
N.N. Burdenko National Medical Research Center of Neurosurgery
ORCID iD: 0000-0001-7045-7223
Moscow
Russian FederationO. I. Budanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-3232-2322
1 Samory Mashela St., Moscow 117997
Russian FederationG. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-2322-5734
1 Samory Mashela St., Moscow 117997
Russian FederationS. K. Gorelyshev
N.N. Burdenko National Medical Research Center of Neurosurgery
ORCID iD: 0000-0003-0984-2039
Moscow
Russian FederationA. I. Karachunskiy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
1 Samory Mashela St., Moscow 117997
Russian FederationReferences
Supplementary files
